Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors


This is an open-label therapeutic efficacy study of Tirosint (levothyroxine sodium) capsules in thyroidectomized patients taking proton pump inhibitors and levothyroxine, evaluating changes in serum levels of TSH upon switch to Tirosint with respect to baseline.

Full Title of Study: “An Open-label Therapeutic Efficacy Study of Tirosint (Levothyroxine Sodium) Capsules in Thyroidectomized Patients Taking Proton Pump Inhibitors”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 15, 2020


  • Drug: levothyroxine sodium capsule
    • after the run-in period, patients will be switched to levothyroxine sodium capsule at the same dose used during run-in
  • Drug: Proton pump inhibitor
    • for the whole study duration all subjects will keep taking their proton pump inhibitor medication, as per prescription and as before inclusion
  • Drug: Levothyroxine Sodium Tablets
    • during the run-in period, subjects will continue taking their levothyroxine sodium tablet medication as per prescription and as before inclusion

Arms, Groups and Cohorts

  • Experimental: levothyroxine sodium capsules
    • levothyroxine sodium capsules 88 to 250 mcg/day (depending on individual needs) for 3 months

Clinical Trial Outcome Measures

Primary Measures

  • TSH (Thyroid Stimulating Hormone)
    • Time Frame: 6 weeks and 12 weeks
    • change in serum levels of TSH upon switch to levothyroxine sodium capsules with respect to baseline

Secondary Measures

  • FT4 (free thyroxine)
    • Time Frame: 6 weeks and 12 weeks
    • change in serum levels of FT4 with respect to baseline
  • TT4 (total thyroxine)
    • Time Frame: 12 weeks
    • change in serum levels of TT4 with respect to baseline
  • FT3 (free triiodothyronine)
    • Time Frame: 6 weeks and 12 weeks
    • change in serum levels of FT3 with respect to baseline
  • TT3 (total triiodothyronine)
    • Time Frame: 6 weeks and 12 weeks
    • change in serum levels of TT3 with respect to baseline

Participating in This Clinical Trial

Inclusion Criteria

1. written informed consent duly read, signed and dated by the subject; 2. aged ≥18 and ≤65 years; 3. history of hypothyroidism due to total thyroidectomy; 4. on stable LT4 doses for at least 6 weeks at screening (≥88 mcg daily and ≤250 mcg daily); 5. TSH at screening ≥0.3 and ≤4.0 mIU/L; 6. history of gastroesophageal reflux disease or associated gastrointestinal issues on prescription PPIs (i.e. omeprazole ≥20 mg daily, or esomeprazole ≥ 20 mg daily, or lansoprazole ≥ 15 mg daily, or pantoprazole ≥ 40 mg daily) for at least 8 weeks before screening visit and for whom chronic therapy with PPIs for the next 5 months has been prescribed; 7. for women, adequate and continuative contraceptive measures until the end of the study, if not in menopause; 8. reasonable assumption of understanding the study and willingness to take part to the study and to comply with protocol requirements. Exclusion Criteria:

1. suspected or ascertained non-compliance with LT4 or PPI therapy; 2. subject requiring changes of levothyroxine dose; 3. use of over-the-counter (OTC) PPIs; 4. history of malabsorption or history of gastric bypass surgery, short-gut syndrome, inflammatory bowel disease and other conditions of the gastrointestinal tract that may affect drug absorption (e.g. celiac disease)3; 5. multiple co-morbidities (e.g. cardiac heart failure, active arrhythmia or history of arrhythmia, particularly atrial fibrillation, uncompensated diabetes mellitus, uncorrected adrenal insufficiency, seriously compromised hepatic, renal and/or respiratory functions); 6. neoplastic pathology, active or in remission for less than 5 years (excluding the basic thyroid pathology); 7. terminal condition; 8. parenteral or assisted enteral feeding; 9. presence of any medical condition or other circumstances which would significantly affect the safety of the subject or decrease the chance of obtaining reliable data, achieving study objectives or completing the study; 10. history of alcoholism, drug abuse or psychiatric diseases that could invalidate the informed consent or limit the subject compliance with protocol requirements; 11. pregnant (positive urine pregnancy test at screening or baseline visits) or breast-feeding subject or subject planning a pregnancy in the next months; 12. known hypersensitivity to the ingredients of the preparation involved in the study3; 13. use of forbidden concomitant medications; 14. regular consumption of soy and soy derivatives, cotton seed meals, walnuts, and dietary fibres; 15. participation in other clinical studies during the 3 months prior to screening; 16. presumption of poor reliability/cooperation; 17. any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • IBSA Institut Biochimique SA
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Kenneth D Burman, MD, Principal Investigator, Medstar Health Research Institute

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.